Your browser doesn't support javascript.
CD8+ T cells: An ineffective armor against prolonged COVID-19 in cancer patients.
Van Oekelen, Oliver; Parekh, Samir.
  • Van Oekelen O; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Parekh S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: samir.parekh@mssm.edu.
Cell Rep Med ; 3(7): 100695, 2022 07 19.
Article in English | MEDLINE | ID: covidwho-2285186
ABSTRACT
In a diverse cohort of cancer patients, Lyudovyk et al.1 show that persistent COVID-19 infection is associated with weaker humoral responses and increased CD8+ T cell responses that are ineffective in clearing virus, particularly in patients receiving B cell-depleting therapies.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100695

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100695